Aptinyx Cashes In Post-Naurex Cache With $65m Series A

Aptinyx Inc., a biotechnology firm developing small molecules that modulate the NMDA receptor to treat neurological disorders, closed a $65m Series A round, capitalizing on the cache that its management team gained from the sale of Naurex Inc. to Allergan PLC.